Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
Public ClinicalTrials.gov record NCT05657860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
Study identification
- NCT ID
- NCT05657860
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Maimonides Medical Center
- Other
- Enrollment
- 15 participants
Conditions and interventions
Conditions
- Abnormalities, Multiple
- Aggression
- Antihypertensive Agents
- Behavioral Symptoms
- Chromosome Disorders
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Intellectual Disability
- Molecular Mechanisms of Pharmacological Action
- Nervous System Diseases
- Neurobehavioral Manifestations
- Neurologic Manifestations
- Neurotransmitter Agents
- Nutrition Disorders
- Obesity
- Overnutrition
- Pathologic Processes
- Physiological Effects of Drugs
- Prader-Willi Syndrome
- Self-Injurious Behavior
- Skin-Picking
Interventions
- Guanfacine Extended Release Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 6 Years to 35 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2020
- Primary completion
- Dec 15, 2023
- Completion
- Dec 15, 2023
- Last update posted
- Aug 18, 2024
2020 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Maimonides Medical Center | Brooklyn | New York | 11219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05657860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2024 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05657860 live on ClinicalTrials.gov.